ID   SCCIC1
AC   CVCL_G300
SY   SCC-IC1; SCC IC1; IC1
DR   cancercelllines; CVCL_G300
DR   CancerTools; 153662
DR   Cosmic; 1608872
DR   Cosmic; 2688662
DR   GEO; GSM2611461
DR   GEO; GSM2611462
DR   GEO; GSM2611463
DR   Wikidata; Q54952379
DR   Ximbio; 153662
RX   PubMed=21602893;
RX   PubMed=22006338;
RX   PubMed=24662767;
RX   PubMed=29755650;
RX   PubMed=30202019;
RX   PubMed=31336867;
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>A; ClinVar=VCV000635365; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Asp154Asn (c.460G>A); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Cys456Ser (c.1366T>A); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Cys456Phe (c.1367G>T); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asn1809His; Zygosity=Unspecified (PubMed=22006338).
CC   Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Pro1913Leu (c.5738C>T); Zygosity=Unspecified (PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Unspecified (PubMed=21602893; PubMed=24662767).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=21602893; PubMed=24662767).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Right temple, skin; UBERON=UBERON_8480028.
ST   Source(s): PubMed=31336867
ST   Amelogenin: X,Y
ST   CSF1PO: 12,14
ST   D13S317: 9,13
ST   D16S539: 9,13
ST   D18S51: 15,17
ST   D19S433: 15,16.2
ST   D21S11: 29,30
ST   D2S1338: 19,25
ST   D3S1358: 14,17
ST   D5S818: 11,13
ST   D7S820: 8,11
ST   D8S1179: 13
ST   FGA: 21,24
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 16
DI   NCIt; C4819; Skin squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VJ58 ! SCCIC1Met
SX   Male
AG   77Y
CA   Cancer cell line
DT   Created: 11-02-13; Last updated: 30-01-24; Version: 18
//
RX   PubMed=21602893; DOI=10.1038/onc.2011.180; PMCID=PMC3219832;
RA   Watt S.A., Pourreyron C., Purdie K.J., Hogan C., Killick-Cole C.L.,
RA   Foster N., Pratt N., Bourdon J.-C., Appleyard M.V.C.L., Murray K.,
RA   Thompson A.M., Mao X., Mein C.A., Bruckner-Tuderman L.K., Evans A.,
RA   McGrath J.A., Proby C.M., Foerster J., Leigh I.M., South A.P.;
RT   "Integrative mRNA profiling comparing cultured primary cells with
RT   clinical samples reveals PLK1 and C20orf20 as therapeutic targets in
RT   cutaneous squamous cell carcinoma.";
RL   Oncogene 30:4666-4677(2011).
//
RX   PubMed=22006338; DOI=10.1073/pnas.1114669108; PMCID=PMC3203814;
RA   Wang N.J., Sanborn Z., Arnett K.L., Bayston L.J., Liao W., Proby C.M.,
RA   Leigh I.M., Collisson E.A., Gordon P.B., Jakkula L.R., Pennypacker S.,
RA   Zou Y., Sharma M., North J.P., Vemula S.S., Mauro T.M., Neuhaus I.M.,
RA   LeBoit P.E., Hur J.S., Park K., Huh N., Kwok P.-Y., Arron S.T.,
RA   Massion P.P., Bale A.E., Haussler D., Cleaver J.E., Gray J.W.,
RA   Spellman P.T., South A.P., Aster J.C., Blacklow S.C., Cho R.J.;
RT   "Loss-of-function mutations in Notch receptors in cutaneous and lung
RT   squamous cell carcinoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:17761-17766(2011).
//
RX   PubMed=24662767; DOI=10.1038/jid.2014.154; PMCID=PMC4753672;
RA   South A.P., Purdie K.J., Watt S.A., Haldenby S., den Breems N.Y.,
RA   Dimon M., Arron S.T., Kluk M.J., Aster J.C., McHugh A., Xue D.J.,
RA   Dayal J.H.S., Robinson K.S., Rizvi S.M.H., Proby C.M., Harwood C.A.,
RA   Leigh I.M.;
RT   "NOTCH1 mutations occur early during cutaneous squamous cell
RT   carcinogenesis.";
RL   J. Invest. Dermatol. 134:2630-2638(2014).
//
RX   PubMed=29755650; DOI=10.18632/oncotarget.24750; PMCID=PMC5945540;
RA   McHugh A., Fernandes K., South A.P., Mellerio J.E., Salas-Alanis J.C.,
RA   Proby C.M., Leigh I.M., Saville M.K.;
RT   "Preclinical comparison of proteasome and ubiquitin E1 enzyme
RT   inhibitors in cutaneous squamous cell carcinoma: the identification of
RT   mechanisms of differential sensitivity.";
RL   Oncotarget 9:20265-20281(2018).
//
RX   PubMed=30202019; DOI=10.1038/s41467-018-06027-1; PMCID=PMC6131170;
RA   Inman G.J., Wang J., Nagano A., Alexandrov L.B., Purdie K.J.,
RA   Taylor R.G., Sherwood V., Thomson J., Hogan S., Spender L.C.,
RA   South A.P., Stratton M.R., Chelala C., Harwood C.A., Proby C.M.,
RA   Leigh I.M.;
RT   "The genomic landscape of cutaneous SCC reveals drivers and a novel
RT   azathioprine associated mutational signature.";
RL   Nat. Commun. 9:3667.1-3667.14(2018).
//
RX   PubMed=31336867; DOI=10.3390/ijms20143428; PMCID=PMC6678499;
RA   Hassan S., Purdie K.J., Wang J., Harwood C.A., Proby C.M.,
RA   Pourreyron C., Mladkova N., Nagano A., Dhayade S., Athineos D.,
RA   Caley M., Mannella V., Blyth K., Inman G.J., Leigh I.M.;
RT   "A Unique panel of patient-derived cutaneous squamous cell carcinoma
RT   cell lines provides a preclinical pathway for therapeutic testing.";
RL   Int. J. Mol. Sci. 20:3428.1-3428.26(2019).
//